(2024). Corrigendum to "Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies". SAGE Publishing.
Chicago Style (17th ed.) CitationCorrigendum to "Eptinezumab Administered Intravenously, Subcutaneously, or Intramuscularly in Healthy Subjects And/or Patients with Migraine: Early Development Studies". SAGE Publishing, 2024.
MLA (9th ed.) CitationCorrigendum to "Eptinezumab Administered Intravenously, Subcutaneously, or Intramuscularly in Healthy Subjects And/or Patients with Migraine: Early Development Studies". SAGE Publishing, 2024.
Warning: These citations may not always be 100% accurate.